LONDON (Alliance News) - Shares rose in N4 Pharma PLC on Monday as a key research study demonstrated positive results for the company's Nuvec delivery system.
Shares in the vaccine and cancer-focused pharmaceutical company rose 29% at 6.30 pence on Monday.
Since June, N4 Pharma has conducted a research study to determine the level of immune response Nuvec can deliver, using both messenger RNA and plasmid DNA when combined with the antigen Ovalbumin.
The results demonstrates that the Nuvec themselves have a clear adjuvant effect to help deliver a level of immune response for both the mRNA and pDNA antigens compared to other delivery systems.
As Nuvec will not require an additional adjuvant when formulating a vaccine when used as a delivery system, this could lead to reduced production costs for a final vaccine, as less antigen would be required.
In addition, the level of immune response generated by Nuvec particles is within acceptable levels, showing no adverse toxicity.
"These results are another positive step forward for our Nuvec delivery platform. The data validates the potential of Nuvec to act as an alternative delivery system for the development of vaccines and cancer treatments but without the associated unwanted systemic side effects and with no signs of liver toxicity often seen using lipid nanoparticle systems," said Chief Executive Officer Nigel Theobald.
"Our next research study will focus on demonstrating the ability of Nuvec to deliver an effective level of immunity using OVA, results of which will be available in first half of 2019," Theobald added.
N4 Pharma Plc (N4P)